Cirrhosis
Treatment in China

Disease Introduction

Liver cirrhosis is the end-stage condition resulting from long-term damage caused by chronic liver diseases such as hepatitis B, hepatitis C, alcoholism, and fatty liver, leading to widespread fibrosis, hardening, and deformation of the liver. Early stages may be asymptomatic, but as it progresses, symptoms such as fatigue, abdominal distension, and jaundice appear. Late-stage complications include ascites, esophageal variceal bleeding, and hepatic encephalopathy. The core of treatment is to eliminate the underlying cause and control complications; liver transplantation is considered in the end-stage.

Cutting-edge high-precision diagnostic and treatment technologies

1. Etiological reversal : Antiviral therapy, abstinence from alcohol, and other etiological control measures can reverse some liver fibrosis, and decompensated stage can be reversed to compensated stage;
2. New anti-fibrotic drug : Hydroxynidone in a Phase III trial combined with entecavir significantly reversed chronic hepatitis B-related liver fibrosis;
3. Targeted degradation : The liver-targeting protein degrader developed by the Chinese Academy of Sciences can control early liver fibrosis and inhibit tumor progression;
4. Non-invasive assessment : FibroScan quantifies liver stiffness in kilopascals and has received strong recommendations from multiple EASL guidelines, avoiding liver biopsy;
5. Precision TIPS : Covered stent combined with varicose vein embolization technology further improves the prognosis of patients with portal hypertension;
6. Hepatitis B cure research : New drugs such as small interfering RNA are advancing clinical research on functional cure (surface antigen clearance) of hepatitis B, which is expected to further reduce the risk of cirrhosis;